rencap logo

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Recent Articles

Published
Jul 26, 2021
Renaissance Capital
IPOs

Cloud-focused Founder SPAC files for a $275 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

SPAC Neo Technology Acquisition files for a $40 million IPO, targeting Asia and North America

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Preclinical biotech Ocean Biomedical cuts valuation by 43% ahead of $50 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Oncology biotech Nuvalent sets terms for $151 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Heart disease biotech Tenaya Therapeutics sets terms for $150 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Intraocular lens platform RxSight sets terms for $125 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Oral capsule developer Rani Therapeutics sets terms for $100 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

AIM-listed cell engineering platform MaxCyte sets terms for $150 million US IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Nutraceutical maker The Better Being Co. sets terms for $200 million IPO

Published
Jul 26, 2021
Renaissance Capital
Published
Jul 26, 2021
Renaissance Capital
IPOs

Language learning platform Duolingo raises range to $95 to $100 ahead of $498 million IPO

Published
Jul 26, 2021
Renaissance Capital
See More
Published

Published